WFRF:(Kivisakk P)
Sökning: WFRF:(Kivisakk P) > Neutralising and bi...
LIBRIS Formathandbok (Information om MARC21)
| Fältnamn | Indikatorer | Metadata |
|---|---|---|
| 000 | 02842naa a2200313 4500 | |
| 001 | oai:prod.swepub.kib.ki.se:1929687 | |
| 003 | SwePub | |
| 008 | 240701s1997 | |||||||||||000 ||eng| | |
| 024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:19296872 URI |
| 024 | 7 | a https://doi.org/10.1177/1352458597003003032 DOI |
| 040 | a (SwePub)ki | |
| 041 | a engb eng | |
| 042 | 9 SwePub | |
| 072 | 7 | a ref2 swepub-contenttype |
| 072 | 7 | a art2 swepub-publicationtype |
| 100 | 1 | a Kivisakk, P4 aut |
| 245 | 1 0 | a Neutralising and binding anti-interferon-beta-I b (IFN-beta-I b) antibodies during IFN-beta-I b treatment of multiple sclerosis |
| 264 | c 2016-07-02 | |
| 264 | 1 | b SAGE Publications,c 1997 |
| 520 | a Interferon-β-1b (IFN-β-1b) is an immunomodulatory therapy of multiple sclerosis (MS), reducing the numbers and severity of exacerbations and the total lesion load measured by magnetic resonance imaging of the brain. The benefits of IFN-β-1b could be hampered by the development of neutralising antibodies against the compound. Our results confirmed earlier studies, showing that 42% of MS patients treated with IFN-β-1b for more than 3 months had developed neutralising antibodies. The occurrence of binding anti-IFN-β-1b antibodies, presently not believed to impede the clinical efficacy of IFN-β-1b, were demonstrated by an immunoassay in some patients already after I month of treatment and in 78% after 3 months. The development of binding antibodies seemed to be an early phenomenon, preceding the appearance of neutralising antibodies. Antibodies crossreacting with IFN-β-1a and natural IFN-β were also found in a majority of IFN-β-1b treated patients with high titres of binding antibodies. Employing a solid-phase enzyme-linked immunospot (ELISPOT) assay, 68% of MS patients treated with IFN-β-1b for 1 -23 months had elevated numbers of anti-IFN-β-1b-antibody secreting cells in blood, compared to 18% of untreated MS patients and 20% among patients with other neurological diseases. Thus, our findings confirm that IFN-β-1 b is immunogenic in MS patients. High levels of anti-IFN-β-1b antibody secreting cells were, however, also found in two untreated control patients with inflammatory diseases, suggesting that anti-IFN-β-1b antibodies might also occur spontaneously. | |
| 700 | 1 | a Alm, GV4 aut |
| 700 | 1 | a Tian, WZ4 aut |
| 700 | 1 | a Matusevicius, D4 aut |
| 700 | 1 | a Fredrikson, Su Karolinska Institutet4 aut |
| 700 | 1 | a Link, Hu Karolinska Institutet4 aut |
| 710 | 2 | a Karolinska Institutet4 org |
| 773 | 0 | t Multiple sclerosis (Houndmills, Basingstoke, England)d : SAGE Publicationsg 3:3, s. 184-190q 3:3<184-190x 1352-4585x 1477-0970 |
| 856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:1929687 |
| 856 | 4 8 | u https://doi.org/10.1177/135245859700300303 |
Hitta via bibliotek
- Multiple sclerosis (Houndmills, Basingstoke, England) (Sök värdpublikationen i LIBRIS)
Till lärosätets databas
Hitta mer i SwePub
- Av författaren/redakt...
- Kivisakk, P
- Alm, GV
- Tian, WZ
- Matusevicius, D
- Fredrikson, S
- Link, H
- Artiklar i publikationen
- Multiple scleros ...
- Av lärosätet
- Karolinska Institutet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
